{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-026810","form_type":"8-K","ticker":"INVA","cik":"0001080014","company_name":"Innoviva, Inc.","filed_at":"2023-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:43.799915+00:00","generated_at":"2026-06-18T20:51:52.195837+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Innoviva reports Q4 2022 royalties of $54.7M, pre-tax loss of $64.7M on $85.4M fair-value decline","bullets":["Gross royalty revenues of $54.7M from GSK for RELVAR/BREO and ANORO ELLIPTA in Q4 2022.","Income before taxes was a loss of $64.7M vs. income of $56.5M in Q4 2021, driven by $85.4M decline in fair value of investments.","Net product sales of $14.6M from GIAPREZA and XERAVA in Q4 2022.","Board authorized $100M share repurchase program; $30M convertible debt facility with Armata closed in January 2023.","FDA granted priority review for SUL-DUR NDA; PDUFA date May 29, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-026810","json":"https://secwatch.observer/filing/0001104659-23-026810.json","markdown":"https://secwatch.observer/filing/0001104659-23-026810.md","text":"https://secwatch.observer/filing/0001104659-23-026810.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1080014/000110465923026810/0001104659-23-026810-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1080014/000110465923026810/tm238049d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T20:51:52.195837+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"009b50cdf77fb8b518703e5678cc01188b3812dd","claim":"Innoviva, Inc. reported financial results for the fourth quarter ended December 31, 2022.","evidence_excerpt":"On February 28, 2023, Innoviva, Inc. (the \"Company\") issued a press release regarding its results of operations and financial condition for the quarter ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1080014/000110465923026810/0001104659-23-026810-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}